Abiopharma

🔍 Zygmont Chester Stanley III (Executive)

Company: REVELATION BIOSCIENCES, INC. (REVB)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Sold 13,285 shares of Common Stock at $1.1 per share (Direct)
  Date: 2026-04-30 | Code: F | equity_swap_involved: false | shares_owned_after: 92,063.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: H | nature_of_ownership: LLC | shares_owned_after: 2.00 | Footnotes: F4

Footnotes:

• F1: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
• F4: Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.